.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
DEFICIENCY OF INTERLEUKIN-1
RECEPTOR ANTAGONIST TREATMENT
About the Disease
Deficiency of Interleukin-1 Receptor Antagonist (DIRA) is an autoinflammatory disease first reported in 2009 that is characterized by the absence of functional interleukin-1 receptor antagonist (IL-1Ra) protein. Patients with DIRA have life-threatening systemic inflammation with skin and bone involvement. DIRA is a genetic disorder inherited in an autosomal recessive manner, meaning that a mutation in both copies of a gene is needed to cause the disease. DIRA is a very rare disease, with fewer than 50 patients worldwide.
About our Patient Care
Our dedicated Care Team works with the physician's office and insurance on a patient's behalf to give our patients more time to focus on their treatment and other important aspects of their lives. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.
As part of treatment and services, we provide:
Dedicated Care Team
We provide prescribers and patients with a dedicated care team for each of our disease-state programs. This includes a primary pharmacy contact, clinical education, side-effect management, scheduled refill calls, and a direct phone, fax, and email address.
Shipping and Coordination of Care
We provide free overnight delivery of medication and necessary medical supplies and manage care coordination between prescribers, sites of care, nurses, and patients to ensure dispense and drug delivery align with the date and location of service.
Financial Assistance
We identify and assist in enrolling qualified patients into manufacturer financial assistance programs to minimize a potential financial burden to patients.
24/7/365 Access to a Pharmacist
We provide prescribers and patients access to a pharmacist 24/7/365 to ensure patients are always cared for.
Supported Treatments
Click on the specialty drug name below to expand and see more information.
ARCALYST® (rilonacept)
Brand Name | ARCALYST® (rilonacept)
Manufacturer | Kiniksa Pharmaceuticals (UK), Ltd.
Route of Administration | Subcutaneous Injection
Approved Indication | ARCALYST (rilonacept) is an interleukin-1 blocker indicated for:
- Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more
- Treatment of Recurrent Pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older
- Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older
Self-Administration | Yes
Product Website | https://arcalyst.com
ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. and is exclusively licensed by Kiniksa Pharmaceuticals.
Partnering with Prescribers
Licensed prescribers can submit a completed enrollment form.
Sources:
Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1 receptor antagonist. N Engl J Med. 2009;360(23):2426-2437.
Lachmann HJ. Periodic fever syndromes. Best Pract Res Clin Rheumatol. 2017;31(4):596-609.
Autosomal dominant inheritance. National Cancer Institute Dictionary of Genetics Terms. Accessed February 23, 2021. https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/autosomal-dominant-inheritanc.
Garg M, de Jesus AA, Chapelle D, et al. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. JCI Insight. 2017;2(16):e94838.